JAGX - Jaguar Health GAAP EPS of -$36.18 revenue of $11.96M
2023-03-27 07:11:00 ET
- Jaguar Health press release ( NASDAQ: JAGX ): FY GAAP EPS of -$36.18.
- Revenue of $11.96M (+175.6% Y/Y).
- Shares +8% PM.
- Patient enrollment in OnTarget Phase 3 clinical trial of crofelemer for prophylaxis of cancer therapy-related diarrhea (CTD) is now at approximately 80% and expected to complete in Q2 2023.
- Jaguar planning to support investigator-initiated proof-of-concept (POC) studies of crofelemer in 2023 for short bowel syndrome ( SBS ) with intestinal failure and congenital diarrheal disorders (CDD). POC targeted for 2H 2023 in support of potential early patient access in Europe, potentially in 2024.
- The Company plans to submit an Investigational New Drug ( IND ) application in Q2 2023 to FDA for crofelemer for microvillus inclusion disease, a rare CDD condition, for which Orphan Drug Designation has been granted by both the FDA and European Medicines Agency.
For further details see:
Jaguar Health GAAP EPS of -$36.18, revenue of $11.96M